Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Adenocarcinoma of Lung 5NSCLC 4Meningeal Carcinomatosis 4Brain Neoplasms 4Lung Neoplasms 3Pleural Effusion, Malignant 1Non Small Cell Lung Cancer NSCLC 1Neoplasm, Residual 1Multiple Primary Lung Cancers 1EGF-R Positive Non-Small Cell Lung Cancer 1Carcinoma 1Adenocarcinoma 1

Interventions

Bevacizumab 7Talc 4Pleurodesis 4Thoracoscopy 3Povidone-Iodine 3Paclitaxel 3Drug Therapy 3Doxycycline 3Docetaxel 3Cisplatin 3Chest Tubes 3Carboplatin 3aldesleukin 2Thoracentesis 2Taxes 2Surveys and Questionnaires 2Sodium Chloride 2Silver Nitrate 2Pharmaceutical Preparations 2Nivolumab 2Magnetic Resonance Spectroscopy 2Interleukin-2 2High-Energy Shock Waves 2Gemcitabine 2Fentanyl 2tocilizumab 1talimogene laherparepvec 1romidepsin 1lipoplatin 1cediranib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pleural Effusion, Malignant × aflutinib × Clear all
NCT07482605 2026-03-20

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Jiangmen Central Hospital

Phase 2 Not yet recruiting
63 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡